Neurogene price target lowered to $45 from $60 at BMO Capital

BMO Capital lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 and keeps an Outperform rating on the shares. The shares are “priced for failure when the longer-term story remains intact” that NGN-401 remains competitive at low-dose, says the analyst, who lowered the firm’s price target to reflect challenges to the narrative given recent updates and headline risk.